Accuray's Q1 Loss Widens to $21.7M Amid Revenue Dip, Soaring Interest Costs

TL;DR

**Accuray's Q1 results are a red flag, with widening losses and revenue declines signaling deep operational and financial challenges.**

AI Summary

Accuray Inc. (ARAY) reported a significant net loss of $21.678 million for the three months ended September 30, 2025, a substantial increase from the $3.954 million net loss in the prior year period. Total net revenue decreased by 7.5% to $93.942 million from $101.545 million, primarily driven by a 23.1% decline in product revenue to $37.161 million. Service revenue, however, increased by 6.8% to $56.781 million. Operating loss widened dramatically to $11.313 million from $2.149 million, exacerbated by a $1.874 million loss from change in fair value of warrant liability and a sharp rise in interest expense to $8.052 million from $2.955 million. The company's cash and cash equivalents increased to $63.344 million from $57.416 million, but total assets decreased to $456.816 million from $470.239 million. Accounts receivable, net, saw a significant reduction from $83.192 million to $54.378 million, while inventories increased to $155.503 million from $141.020 million. The company faces ongoing risks from macroeconomic conditions, supply chain challenges, and compliance with debt covenants.

Why It Matters

This filing reveals a concerning deterioration in Accuray's financial performance, with a significantly widened net loss and declining product revenue. For investors, the substantial increase in interest expense and the loss from warrant liability indicate rising financial leverage and potential dilution, impacting shareholder value. Employees might face uncertainty given the operational losses and ongoing macroeconomic headwinds. Customers could experience potential impacts on product availability or service quality if financial pressures persist. The broader market for advanced radiosurgery and radiation therapy systems may see Accuray's competitive position weaken, potentially benefiting rivals if Accuray struggles to invest in R&D or expand market share effectively.

Risk Assessment

Risk Level: high — The risk level is high due to a significant increase in net loss to $21.678 million from $3.954 million year-over-year, coupled with a 7.5% decline in total net revenue. The company also faces substantial financial risk from increased interest expense of $8.052 million and a $1.874 million loss from the change in fair value of warrant liability, indicating rising debt costs and potential dilution. Furthermore, the filing explicitly mentions risks related to compliance with debt covenants, including financial covenants regarding the consolidated fixed charge coverage ratio, consolidated leverage ratio, and minimum liquidity requirements, with a failure potentially leading to debt acceleration.

Analyst Insight

Investors should consider reducing exposure to ARAY given the significant widening of net loss, declining product revenue, and increasing financial leverage. Monitor future filings closely for improvements in revenue growth, especially product sales, and any signs of better cost control or debt management. Await clearer indications of the company's ability to navigate macroeconomic headwinds and meet debt covenants before considering new positions.

Financial Highlights

debt To Equity

2.04

revenue

$93.942 million

operating Margin

-12.04%

total Assets

$456.816 million

total Debt

$139.169 million

net Income

-$21.678 million

eps

N/A

gross Margin

N/A

cash Position

$63.344 million

revenue Growth

-7.5%

Revenue Breakdown

Key Numbers

• $21.678 million — Net loss for Q1 2025 (Increased from $3.954 million in Q1 2024, representing a significant deterioration.)
• $93.942 million — Total net revenue for Q1 2025 (Decreased by 7.5% from $101.545 million in Q1 2024.)
• $37.161 million — Product revenue for Q1 2025 (Declined by 23.1% from $48.369 million in Q1 2024.)
• $56.781 million — Service revenue for Q1 2025 (Increased by 6.8% from $53.176 million in Q1 2024.)
• $11.313 million — Loss from operations for Q1 2025 (Widened from $2.149 million in Q1 2024.)
• $8.052 million — Interest expense for Q1 2025 (Increased significantly from $2.955 million in Q1 2024.)
• $1.874 million — Loss from change in fair value of warrant liability for Q1 2025 (A new expense not present in Q1 2024.)
• $63.344 million — Cash and cash equivalents as of September 30, 2025 (Increased from $57.416 million as of June 30, 2025.)
• $54.378 million — Accounts receivable, net, as of September 30, 2025 (Decreased from $83.192 million as of June 30, 2025.)
• $155.503 million — Inventories, net, as of September 30, 2025 (Increased from $141.020 million as of June 30, 2025.)

Key Players & Entities

• ACCURAY INCORPORATED (company) — registrant
• Delaware (regulator) — state of incorporation
• Nasdaq Stock Market LLC (regulator) — exchange where common stock is registered
• SEC (regulator) — Securities and Exchange Commission
• FASB (regulator) — Financial Accounting Standards Board
• Madison, Wisconsin (person) — headquarters location
• China (person) — primary office location and geopolitical risk factor
• United States (person) — primary office location and market for radiotherapy equipment
• Switzerland (person) — primary office location
• Japan (person) — primary office location

FAQ

Risk Factors

• Increased Interest Expense [high — financial]: Interest expense rose sharply to $8.052 million from $2.955 million in the prior year period, significantly contributing to the widened net loss. This increase puts additional pressure on profitability.
• Warrant Liability Revaluation [medium — financial]: The company recognized a $1.874 million loss from the change in fair value of warrant liability. This is a new expense compared to the prior year and negatively impacted net income.
• Inventory Build-up [medium — operational]: Inventories increased to $155.503 million from $141.020 million. This could indicate slower sales or production issues, tying up working capital.
• Decreased Total Assets [medium — financial]: Total assets decreased to $456.816 million from $470.239 million, reflecting a contraction in the company's balance sheet.
• Reduced Accounts Receivable [medium — financial]: Accounts receivable, net, decreased significantly from $83.192 million to $54.378 million. While this improves cash collection, it is also linked to the decline in product revenue.
• Debt Covenant Compliance [high — financial]: The company faces ongoing risks related to compliance with debt covenants, which could lead to financial distress if not managed effectively.
• Supply Chain Challenges [medium — operational]: The company continues to face risks from supply chain challenges, which can impact production, costs, and delivery timelines.
• Macroeconomic Conditions [medium — market]: Ongoing risks from macroeconomic conditions could negatively affect customer demand and the company's overall financial performance.

Industry Context

Accuray Inc. operates in the medical device industry, specifically focusing on radiation oncology systems. The sector is characterized by high R&D costs, long sales cycles, and significant regulatory oversight. Competition comes from established players and emerging technologies, with a growing emphasis on precision medicine and minimally invasive treatments.

Regulatory Implications

As a medical device manufacturer, Accuray is subject to stringent regulations from bodies like the FDA in the U.S. and similar agencies globally. Compliance with quality standards, manufacturing processes, and product approvals is critical. Any failures in regulatory compliance can lead to product recalls, fines, and reputational damage, impacting market access and financial performance.

What Investors Should Do

1. Monitor product revenue trends closely.
2. Analyze the drivers of increased interest expense.
3. Assess inventory management effectiveness.
4. Evaluate the impact of warrant liability changes.
5. Scrutinize debt covenant compliance.

Glossary

Warrant Liability

A financial instrument that gives the holder the right, but not the obligation, to purchase a company's stock at a specified price within a certain timeframe. Changes in the fair value of these warrants are recognized in earnings. (A new loss of $1.874 million from the change in fair value of warrant liability impacted the company's net loss for the period.)

Deferred Revenue

Revenue that has been received by a company but not yet earned. It is recorded as a liability until the goods or services are delivered. (Deferred revenue remains a significant liability, with $79.631 million current and $25.824 million non-current, indicating future revenue streams tied to existing contracts.)

Accumulated Deficit

The cumulative net losses of a company since its inception, less any net gains. It represents a negative retained earnings balance. (The accumulated deficit increased to $540.950 million, reflecting the company's ongoing net losses.)

Operating Lease Right-of-Use Assets

Assets recognized under accounting standards for leases, representing the right to use an asset for the lease term. (These assets, along with corresponding liabilities, represent the company's long-term lease obligations for property and equipment.)

Goodwill

An intangible asset that arises when a company acquires another company for a price greater than the fair value of its identifiable net assets. (Goodwill of $57.820 million remains on the balance sheet, indicating past acquisitions.)

Year-Over-Year Comparison

Compared to the prior year period, Accuray Inc. experienced a significant deterioration in financial performance. Total net revenue declined by 7.5% to $93.942 million, primarily due to a sharp 23.1% drop in product revenue, although service revenue saw a modest 6.8% increase. The operating loss widened substantially from $2.149 million to $11.313 million. Key contributing factors to the widened loss include a dramatic increase in interest expense to $8.052 million from $2.955 million and a new $1.874 million loss from the change in fair value of warrant liability. While cash and cash equivalents increased, total assets decreased, and inventories rose, indicating potential working capital pressures.

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value per share ARAY The Nasdaq

Filing Documents

• aray-20250930.htm (10-Q) — 2871KB
• aray-ex31_1.htm (EX-31.1) — 21KB
• aray-ex31_2.htm (EX-31.2) — 21KB
• aray-ex32_1.htm (EX-32.1) — 14KB
• 0001193125-25-266985.txt ( ) — 12410KB
• aray-20250930.xsd (EX-101.SCH) — 1638KB
• aray-20250930_htm.xml (XML) — 2420KB

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 27 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 36 Item 4.

Controls and Procedures

Controls and Procedures 37 PART II. Other Information Item 1.

Legal Proceedings

Legal Proceedings 38 Item 1A.

Risk Factors

Risk Factors 38 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 73 Item 3. Defaults Upon Senior Securities 73 Item 4. Mine Safety Disclosures 73 Item 5. Other Information 73 Item 6. Exhibits 74

Signatures

Signatures 75 We own or have rights to various trademarks and tradenames used in our business in the United States or other countries, including the following: Accuray , Accuray Logo , CyberKnife , HiArt , RoboCouch , Synchrony , TomoTherapy , Xsight , Accuray Precision , AutoSegmentation, CTrue, H Series, iDMS , InCise, Iris, CyberKnife M6 Series, Accuray OIS Connect, PreciseART , PreciseRTX , Treatment Planning System, TomoDirect, TomoEDGE, TomoH , TomoHD , TomoHDA, TomoHelical, TomoTherapy Quality Assurance, Radixact , Onrad , S7, Accuray Helix, CyberComm, AEX , ClearRT , XChange , and VoLO. 2

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Unaudited Condensed Con solidated Financial Statements

Item 1. Unaudited Condensed Con solidated Financial Statements Accuray Incorporated Unaudited Condensed Cons olidated Balance Sheets (in thousands, except share amounts and par value) September 30, 2025 June 30, 2025 ASSETS Current assets: Cash and cash equivalents $ 63,344 $ 57,416 Restricted cash 572 574 Accounts receivable, net of allowance for credit losses of $ 1,079 and $ 369 as of September 30, 2025, and June 30, 2025, respectively (a) 54,378 83,192 Inventories, net 155,503 141,020 Prepaid expenses and other current assets (b) 29,373 33,501 Deferred cost of revenue 433 1,762 Total current assets 303,603 317,465 Noncurrent assets: Property and equipment, net 29,013 28,658 Investment in joint venture 4,010 4,612 Operating lease right-of-use assets, net 32,099 33,115 Goodwill 57,820 57,802 Restricted cash 6,012 4,144 Other assets 24,259 24,443 Total assets $ 456,816 $ 470,239 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 42,400 $ 34,033 Accrued compensation 13,907 14,573 Operating lease liabilities, current 7,463 7,375 Other accrued liabilities 26,271 29,361 Customer advances 12,087 12,197 Deferred revenue 79,631 82,306 Short-term debt, net 12,853 12,734 Total current liabilities 194,612 192,579 Noncurrent liabilities: Operating lease liabilities, non-current 31,481 32,482 Long-term other liabilities 5,345 5,160 Warrant liability 10,371 8,497 Deferred revenue, non-current 25,824 26,566 Long-term debt, net 127,316 123,786 Total liabilities 394,949 389,070 Commitments and contingencies (Note 7 ) Stockholders' equity: Common stock, $ 0.001 par value; authorized: 200,000,000 shares as of September 30, 2025, and June 30, 2025, respectively; issued and outstanding: 113,281,068 and 112,643,852 shares at September 30, 2025, and June 3

View Full Filing

View this 10-Q filing on SEC EDGAR